Yuying Xie

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu et al. · Blood · 2020 · 57 citations

Medicine, Oncology, Pharmacology +10

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Martin Hutchings, Carmelo Carlo‐Stella, Franck Morschhauser et al. · Blood · 2023 · 33 citations

Medicine, Oncology, Pharmacology +17

Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment

Martin Hutchings, Carmelo Carlo‐Stella, Franck Morschhauser et al. · Blood · 2022 · 19 citations

Medicine, Hematology, Oncology +9

Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

Valentina Gambardella, Michael Ong, María E. Rodríguez-Ruiz et al. · Cancer Research Communications · 2025 · 16 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.

Lorenzo Falchi, Carmelo Carlo‐Stella, Franck Morschhauser et al. · Journal of Clinical Oncology · 2023 · 15 citations

Medicine, Oncology, Pharmacology +17